3 ms·
> the patentability of modifications to existing drugs under Indian law A key point here is that the original drug itself was patented, and has expired. The is
by belorn 14y ago
> the patentability of modifications to existing drugs under Indian law
A key point here is that the original drug itself was patented, and has expired. The issue that the Indian court had with Gleevec patent application is that it only rearranged the molecule in a new crystal pattern, ie Polymorphism. The Indian court consider polymorphism to be a well known technique when working with drugs, and just applying polymorphism to a old drug and record what it did do not fulfill the requirement for patentable.
- rohamg 14y agoThis. The US patent system rewards the same kind of "innovation" as the financial sector did pre-subprime. Look at the introduction rate of new drugs vs derivatives of old (and about to expire) drugs over the past decades to see what I mean. The argument that "if drugs were cheaper (=they saved more lives) pharma r&d would crumble" is facetious and speaks volumes about the priorities of the individual making the argument.
- nikster 14y agoThe US patent and IP system is completely perverted. The reason to have copyrights and patents is to fairly compensate the innovators (that part works really well). But there's an expiry on both patents and copyright - that's explicitly there so innovations can benefit the people, and to spur new innovation. And that's where the US system falls apart. Loopholes are found times and again and in the US once you have a copyright or patent, you basically have it forever. A monopoly, hurrah! That's just plain wrong. The US needs to fix its system. I imagine when that happens it will also make more sense for Pharma industry to spend more on R&D than they spend on marketing and bribing Doctors and healthcare providers and politicians. Really happy to hear Indian courts don't fall for this sort of crap. How can Disney have a copyright on Mickey Mouse? An absolute joke.
- TheCondor 14y agoSeems like there should be a penalty for evergreening patents like this without some measurable improvement in product quality. I might have different feelings about it if India just rejected the initial patent, but the reapsearch has been paid for, profits taken...